

**Sonata reported a better-than-expected operating performance on margin beat.** IITS revenue grew 0.2% QoQ to USD82mn (1% CC), in line with our expectations. Revenue growth was lopsided, with RMD driving growth while the rest of the verticals either reported muted revenue or decline on a sequential basis. IITS EBITDAM rose by 70bps QoQ to 17.3%, above our expectations, despite the wage hike. Sonata reported order bookings of USD105mn (10% were AI-led) and a book-to-bill ratio of 1.28x. Revenue growth was impacted by the continued ramp-down of a large BFSI client due to budget constraints, softness in the largest TMT client account, and domestic SITL headwinds, though partially offset by ramp-ups in large HLS and TMT deals and mid-sized AI wins. Despite the second phase of wage hike for mid-to-senior employees in Q3, the management expects IITS EBITDAM recovery to sustain in H2 on operating efficiencies, driven by higher utilization, offshore shift, pyramid rationalization, and AI-led productivity improvement. The company aspires to operate at a high-teen EBITDAM in the near term and aims for low twenties in the medium term. The management expects profit growth in H2 vs H1. Factoring in the Q2 performance and near-term growth challenges, we tweaked our FY26-28E EPS by -5% to 4%. We retain BUY, with an unchanged TP of Rs400, at 18x Sep-27E EPS.

### Results Summary

IITS revenue grew 0.2% QoQ to USD82mn (1% CC), in line with our estimate. IITS revenue performance was skewed, driven by RMD (up 10.3% QoQ, aided by certain one-offs), while the other verticals reported either muted revenue or decline QoQ (Emerging 24.8%, BFSI 4.8%, TMT 2.9%, HLS flattish). Among geographies, the US declined 6.5% QoQ, while Europe/the RoW grew 12.8%/30.3%, respectively. IITS EBITDAM rose by 70bps QoQ to 17.3% on operating efficiencies, led by utilization, offshore shift, delivery efficiencies, and currency benefits (+160bps) negating the wage hike (-90bps). Overall EBITDAM grew by 280bps QoQ to 8.1%. IITS headcount fell 4.0% QoQ to 6,136. Gross contribution grew 0.3% QoQ in the domestic business. Sonata declared an interim dividend of Rs1.25/sh.

**What we like:** Margin beat, steady deal intake. **What we do not like:** Revenue miss, continued client-specific issues in BFSI and TMT.

### Earnings Call KTA

1) Headwinds from the largest BFSI client, driven by organizational changes and budget constraints, impacted BFSI growth in Q2, with a residual impact expected in Q3 before growth resumes in the vertical. 2) In TMT, softness in the largest client account was partly offset by traction among smaller and mid-sized tech accounts. 3) The company also won a major multi-year large deal in Q2 from a leading US healthcare provider to modernize core platforms using automation and AI....(contd)...

Target Price – 12M	Sep-26
Change in TP (%)	-
Current Reco.	BUY
Previous Reco.	BUY
Upside/(Downside) (%)	7.0

Stock Data	SSOF IN
52-week High (Rs)	687
52-week Low (Rs)	286
Shares outstanding (mn)	280.4
Market-cap (Rs bn)	105
Market-cap (USD mn)	1,182
Net-debt, FY26E (Rs mn)	2,674.9
ADTV-3M (mn shares)	2
ADTV-3M (Rs mn)	668.6
ADTV-3M (USD mn)	7.5
Free float (%)	69.2
Nifty-50	25,910.1
INR/USD	88.7

### Shareholding, Sep-25

Promoters (%)	28.2
FPIs/MFs (%)	8.9/26.3

### Price Performance

(%)	1M	3M	12M
Absolute	2.9	4.0	(33.1)
Rel. to Nifty	(0.1)	(1.1)	(39.2)

### 1-Year share price trend (Rs)



### Sonata Software: Financial Snapshot (Consolidated)

Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Revenue	86,131	101,573	100,458	104,023	119,412
EBITDA	7,274	6,892	6,515	7,806	9,440
Adj. PAT	4,832	4,247	4,287	5,232	6,729
Adj. EPS (Rs)	17.2	15.1	15.3	18.7	24.0
EBITDA margin (%)	8.4	6.8	6.5	7.5	7.9
EBITDA growth (%)	20.4	(5.2)	(5.5)	19.8	20.9
Adj. EPS growth (%)	6.9	(12.1)	0.9	22.1	28.6
RoE (%)	35.7	27.3	23.2	24.1	26.0
RoIC (%)	46.5	34.1	24.1	27.1	33.9
P/E (x)	34.0	24.7	24.5	20.1	15.6
EV/EBITDA (x)	15.2	16.0	17.0	14.2	11.7
P/B (x)	7.5	6.2	5.3	4.5	3.7
FCFF yield (%)	2.5	5.2	3.4	4.2	5.8

Source: Company, Emkay Research

### Dipeshkumar Mehta

dipeshkumar.mehta@emkayglobal.com  
+91-22-66121253

### Jimit Gandhi

jimit.gandhi@emkayglobal.com  
+91-22-66121255

### Shivang Bagla

shivang.bagla@emkayglobal.com  
+91-22-66242491

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com)

...(contd)...4) RMD growth rebounded in Q3, largely on the back of certain one-offs. Excluding one-offs, performance remained muted due to industry-wide slowdowns and tariff-related challenges; however, the management expects stabilization and a return to growth within two to three quarters. 5) The company aims to scale up HLS and BFSI verticals to USD250mn revenue in 3-5 years. 6) The mgmt highlighted that Sonata continues to benefit from three tailwinds: i) large TMT and healthcare deals ramping up with wider scopes, ii) HLS and BFSI seeing healthy demand, supported by data-led and AI-led wins, iii) operational efficiency improving through higher utilization (87.3% in Q2 vs 86.6% in Q1), planned offshoring (57% in Q2 vs 53% in Q1), and greater AI and agentic adoption. 7) It noted that large deals remain central to the company's strategy, representing ~40% of the pipeline, with 28 large deals (RMD:14, TMT:7, BFSI:5, HLS:2) in the pipeline (expected to take around 4-6 quarters to close). 8) Overall, the pipeline is heavily geared toward modernization, with cloud and data initiatives accounting for ~55% of total opportunities. 9) AI momentum continues to build, with AI-led deal pipeline of ~USD293mn in Q2 and an AI order book of USD10.8mn. The AI order book grew from 8% to 10% of the overall order book sequentially. The company is actively pursuing AI opportunities across 100+ clients, helping them unlock value through operational efficiencies, time-to-market, and transformative business models through AI innovation. The pipeline for Microsoft Fabric stood at USD45mn. 10) 94.8% of the workforce and 80% of managers are AI-trained. The company also rolled out WIPE coding training, with 78% of the employees successfully completing it. 11) In SITL, Sonata continues to execute its three-pillar strategy: i) driving growth in Microsoft SMC (small, medium, corporate) accounts, ii) expanding AI-led partnerships with other ISVs such as Oracle, IBM, OpenText, etc, and iii) securing large system integration deals. 12) Quant Systems' founder, Srinivasa Veeravelli, decided to pursue opportunities outside of Sonata. The company has hired a new sales leader for Quant Systems to drive the next phase of growth. 13) The mgmt has stated that it intends to adopt a quarterly interim dividend policy starting this year. 14) Gross cash stood at Rs3.23bn, while net debt stood at Rs2.8bn.

#### Exhibit 1: Quarterly snapshot

(Rs mn)	Q2FY26	Q1FY26	QoQ (%)	Q2FY25	YoY (%)
IITS revenue (USD mn)	82.0	81.8	0.2	84.6	(3.1)
Net sales	21,193	29,652	(28.5)	21,698	(2.3)
Operating expenses	19,466	28,055		19,926	
EBITDA	1,727	1,597	8.2	1,773	(2.6)
- Margin (%)	8.1	5.4	280.0	8.2	-
Depreciation	263	261		329	
EBIT	1,464	1,336	9.6	1,443	1.5
- Margin (%)	6.9	4.5	240.0	6.7	30.0
Interest paid	142	51		192	
Other income	314	242		192	
Pre-tax profit	1,636	1,527	7.1	1,443	
Tax provided	434	434		379	
Profit after tax	1,202	1,093		1,065	
Emkay Net profit	1,202	1,093	9.9	1,065	12.9
EPS (Rs)	4.3	3.9	9.9	3.8	12.9

Source: Company, Emkay Research

#### Exhibit 2: Actuals vs estimates


(Rs mn)	Actual	Estimate		Variation		Comment
		Emkay	Consensus	Emkay	Consensus	
Sales	21,193	23,938	25,807	-11.5%	-17.9%	Revenue missed expectations due to a miss in the domestic business, however, IITS revenue came broadly in-line with estimates.
EBIT	1,464	1,173	1,210	24.9%	21.0%	
EBIT margin	6.9%	4.9%	4.7%	200 bps	220 bps	Margin beat estimates across IITS and domestic business.
PAT	1,202	878	1,002	36.9%	20.0%	Profit beat estimates due to margin beat.

Source: Company, Bloomberg, Emkay Research

**Exhibit 3: Changes in estimates**

(Rs mn)	FY26E			FY27E			FY28E		
	Old	New	Chg	Old	New	Chg	Old	New	Chg
IITS - Revenue (USD mn)	333.7	328.6	-1.5%	370.4	361.6	-2.4%	418.4	408.8	-2.3%
Revenue	106,649	100,458	-5.8%	115,652	104,023	-10.1%	130,261	119,412	-8.3%
EBIT	5,388	5,413	0.5%	7,258	6,708	-7.6%	8,714	8,371	-3.9%
EBIT margin	5.1%	5.4%		6.3%	6.4%		6.7%	7.0%	
Net profit	4,130	4,287	3.8%	5,503	5,232	-4.9%	6,803	6,729	-1.1%
EPS (Rs)	14.7	15.3	3.8%	19.6	18.7	-4.9%	24.3	24.0	-1.1%

Source: Company, Emkay Research

**Exhibit 4: SSOF – One-year forward PER**

Source: Company, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com)

## Sonata Software: Consolidated Financials and Valuations

### Profit & Loss

Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
<b>Revenue</b>	<b>86,131</b>	<b>101,573</b>	<b>100,458</b>	<b>104,023</b>	<b>119,412</b>
Revenue growth (%)	15.6	17.9	(1.1)	3.5	14.8
<b>EBITDA</b>	<b>7,274</b>	<b>6,892</b>	<b>6,515</b>	<b>7,806</b>	<b>9,440</b>
EBITDA growth (%)	20.4	(5.2)	(5.5)	19.8	20.9
Depreciation & Amortization	1,319	1,215	1,102	1,097	1,068
<b>EBIT</b>	<b>5,955</b>	<b>5,678</b>	<b>5,413</b>	<b>6,708</b>	<b>8,371</b>
EBIT growth (%)	9.3	(4.7)	(4.7)	23.9	24.8
Other operating income	-	-	-	-	-
Other income	1,256	712	819	625	819
Financial expense	850	653	413	358	218
<b>PBT</b>	<b>6,360</b>	<b>5,737</b>	<b>5,818</b>	<b>6,976</b>	<b>8,973</b>
Extraordinary items	(1,747)	0	0	0	0
Taxes	1,529	1,490	1,531	1,744	2,243
Minority interest	0	0	0	0	0
Income from JV/Associates	-	-	-	-	-
<b>Reported PAT</b>	<b>3,085</b>	<b>4,247</b>	<b>4,287</b>	<b>5,232</b>	<b>6,729</b>
PAT growth (%)	(31.7)	37.7	0.9	22.1	28.6
<b>Adjusted PAT</b>	<b>4,832</b>	<b>4,247</b>	<b>4,287</b>	<b>5,232</b>	<b>6,729</b>
<b>Diluted EPS (Rs)</b>	<b>17.2</b>	<b>15.1</b>	<b>15.3</b>	<b>18.7</b>	<b>24.0</b>
Diluted EPS growth (%)	6.9	(12.1)	0.9	22.1	28.6
<b>DPS (Rs)</b>	<b>7.8</b>	<b>4.4</b>	<b>4.9</b>	<b>5.9</b>	<b>7.5</b>
<b>Dividend payout (%)</b>	<b>71.0</b>	<b>28.9</b>	<b>32.4</b>	<b>31.8</b>	<b>31.3</b>
EBITDA margin (%)	8.4	6.8	6.5	7.5	7.9
EBIT margin (%)	6.9	5.6	5.4	6.4	7.0
Effective tax rate (%)	24.0	26.0	26.3	25.0	25.0
<b>NOPLAT (pre-IndAS)</b>	<b>4,524</b>	<b>4,203</b>	<b>3,988</b>	<b>5,031</b>	<b>6,279</b>
Shares outstanding (mn)	280	280	280	280	280

Source: Company, Emkay Research

### Balance Sheet

Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
Share capital	278	278	278	278	278
Reserves & Surplus	13,785	16,782	19,681	23,248	27,870
<b>Net worth</b>	<b>14,063</b>	<b>17,059</b>	<b>19,959</b>	<b>23,526</b>	<b>28,147</b>
Minority interests	0	0	0	0	0
Non-current liab. & prov.	355	137	(517)	(1,190)	(1,480)
<b>Total debt</b>	<b>6,743</b>	<b>4,416</b>	<b>5,119</b>	<b>3,619</b>	<b>1,119</b>
<b>Total liabilities &amp; equity</b>	<b>22,073</b>	<b>22,357</b>	<b>25,306</b>	<b>26,700</b>	<b>28,531</b>
Net tangible fixed assets	1,327	1,036	969	1,008	1,066
Net intangible assets	4,248	3,862	3,528	3,035	2,550
Net ROU assets	810	636	577	595	651
Capital WIP	0	0	0	0	0
Goodwill	11,135	11,397	11,397	11,397	11,397
Investments [JV/Associates]	5,740	3,880	3,536	3,536	3,536
<b>Cash &amp; equivalents</b>	<b>5,360</b>	<b>3,100</b>	<b>2,444</b>	<b>3,906</b>	<b>5,676</b>
Current assets (ex-cash)	22,796	23,421	23,394	24,412	27,616
Current Liab. & Prov.	28,534	24,339	19,963	20,593	23,310
<b>NWC (ex-cash)</b>	<b>(5,738)</b>	<b>(918)</b>	<b>3,431</b>	<b>3,819</b>	<b>4,306</b>
<b>Total assets</b>	<b>22,073</b>	<b>22,097</b>	<b>25,186</b>	<b>26,580</b>	<b>28,411</b>
Net debt	1,383	1,316	2,675	(287)	(4,557)
Capital employed	22,073	22,357	25,306	26,700	28,531
<b>Invested capital</b>	<b>10,163</b>	<b>14,481</b>	<b>18,629</b>	<b>18,544</b>	<b>18,549</b>
BVPS (Rs)	50.1	60.8	71.2	83.9	100.4
Net Debt/Equity (x)	0.1	0.1	0.1	-	(0.2)
Net Debt/EBITDA (x)	0.2	0.2	0.4	-	(0.5)
Interest coverage (x)	8.5	9.8	15.1	20.5	42.2
<b>RoCE (%)</b>	<b>37.2</b>	<b>30.2</b>	<b>26.8</b>	<b>28.1</b>	<b>32.6</b>

Source: Company, Emkay Research

### Cash flows

Y/E Mar (Rs mn)	FY24	FY25	FY26E	FY27E	FY28E
PBT (ex-other income)	4,614	5,737	5,818	6,976	8,973
Others (non-cash items)	2,908	1,312	1,102	1,097	1,068
Taxes paid	(2,623)	(1,636)	(2,185)	(2,417)	(2,533)
Change in NWC	(2,094)	1,030	(256)	(388)	(487)
<b>Operating cash flow</b>	<b>2,805</b>	<b>6,443</b>	<b>4,479</b>	<b>5,268</b>	<b>7,021</b>
Capital expenditure	1	(678)	(702)	(642)	(642)
Acquisition of business	(726)	(5,919)	(4,093)	0	0
Interest & dividend income	332	213	0	0	0
<b>Investing cash flow</b>	<b>(543)</b>	<b>(4,356)</b>	<b>(4,451)</b>	<b>(642)</b>	<b>(642)</b>
Equity raised/(repaid)	36	35	0	0	0
Debt raised/(repaid)	1,726	(2,465)	703	(1,500)	(2,500)
Payment of lease liabilities	(334)	(293)	0	0	0
Interest paid	(324)	(384)	0	0	0
Dividend paid (incl tax)	(2,189)	(1,226)	(1,387)	(1,664)	(2,108)
Others	0	0	0	0	0
<b>Financing cash flow</b>	<b>(1,085)</b>	<b>(4,333)</b>	<b>(684)</b>	<b>(3,164)</b>	<b>(4,608)</b>
Net chg in Cash	1,177	(2,246)	(656)	1,462	1,770
OCF	2,805	6,443	4,479	5,268	7,021
Adj. OCF (w/o NWC chg.)	4,900	5,413	4,735	5,656	7,508
FCFF	2,806	5,766	3,777	4,626	6,379
FCFE	2,289	5,326	3,364	4,268	6,161
OCF/EBITDA (%)	38.6	93.5	68.8	67.5	74.4
FCFE/PAT (%)	74.2	125.4	78.5	81.6	91.5
<b>FCFF/NOPLAT (%)</b>	<b>62.0</b>	<b>137.2</b>	<b>94.7</b>	<b>91.9</b>	<b>101.6</b>

Source: Company, Emkay Research

### Valuations and key Ratios

Y/E Mar	FY24	FY25	FY26E	FY27E	FY28E
P/E (x)	34.0	24.7	24.5	20.1	15.6
EV/CE(x)	5.3	5.1	4.4	4.1	3.8
P/B (x)	7.5	6.2	5.3	4.5	3.7
EV/Sales (x)	1.3	1.1	1.1	1.1	0.9
EV/EBITDA (x)	15.2	16.0	17.0	14.2	11.7
EV/EBIT(x)	18.6	19.5	20.4	16.5	13.2
EV/IC (x)	10.9	7.6	5.9	6.0	6.0
FCFF yield (%)	2.5	5.2	3.4	4.2	5.8
FCFE yield (%)	2.2	5.1	3.2	4.1	5.9
Dividend yield (%)	2.1	1.2	1.3	1.6	2.0
<b>DuPont-RoE split</b>					
Net profit margin (%)	5.6	4.2	4.3	5.0	5.6
Total asset turnover (x)	4.3	4.8	4.4	4.1	4.4
Assets/Equity (x)	1.5	1.4	1.2	1.2	1.0
<b>RoE (%)</b>	<b>35.7</b>	<b>27.3</b>	<b>23.2</b>	<b>24.1</b>	<b>26.0</b>
<b>DuPont-RoIC</b>					
NOPLAT margin (%)	5.3	4.1	4.0	4.8	5.3
IC turnover (x)	8.9	8.2	6.1	5.6	6.4
<b>RoIC (%)</b>	<b>46.5</b>	<b>34.1</b>	<b>24.1</b>	<b>27.1</b>	<b>33.9</b>
<b>Operating metrics</b>					
Core NWC days	(24.3)	(3.3)	12.5	13.4	13.2
<b>Total NWC days</b>	<b>(24.3)</b>	<b>(3.3)</b>	<b>12.5</b>	<b>13.4</b>	<b>13.2</b>
Fixed asset turnover	4.9	5.7	5.5	5.5	6.2
Opex-to-revenue (%)	24.0	23.5	23.6	25.0	24.7

Source: Company, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com)

## RECOMMENDATION HISTORY - DETAILS

Date	Closing Price (Rs)	TP (Rs)	Rating	Analyst
01-Oct-25	348	400	Buy	Dipeshkumar Mehta
31-Jul-25	392	475	Buy	Dipeshkumar Mehta
01-Jul-25	410	475	Buy	Dipeshkumar Mehta
08-May-25	393	475	Buy	Dipeshkumar Mehta
31-Mar-25	346	500	Buy	Dipeshkumar Mehta
07-Feb-25	489	700	Buy	Dipeshkumar Mehta
01-Jan-25	605	780	Buy	Dipeshkumar Mehta
05-Dec-24	670	780	Buy	Dipeshkumar Mehta

Source: Company, Emkay Research

## RECOMMENDATION HISTORY - TREND



Source: Company, Bloomberg, Emkay Research

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com)

## GENERAL DISCLOSURE/DISCLAIMER BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Emkay Global Financial Services Limited (CIN-L67120MH1995PLC084899) and its affiliates are a full-service, brokerage, investment banking, investment management and financing group. Emkay Global Financial Services Limited (EGFSL) along with its affiliates are participants in virtually all securities trading markets in India. EGFSL was established in 1995 and is one of India's leading brokerage and distribution house. EGFSL is a corporate trading member of BSE Limited (BSE), National Stock Exchange of India Limited (NSE), MCX Stock Exchange Limited (MCX-SX), Multi Commodity Exchange of India Ltd (MCX) and National Commodity & Derivatives Exchange Limited (NCDEX) (hereinafter referred to be as "Stock Exchange(s)"). EGFSL along with its [affiliates] offers the most comprehensive avenues for investments and is engaged in the businesses including stock broking (Institutional and retail), merchant banking, commodity broking, depository participant, portfolio management and services rendered in connection with distribution of primary market issues and financial products like mutual funds, fixed deposits. Details of associates are available on our website i.e. [www.emkayglobal.com](http://www.emkayglobal.com).

EGFSL is registered as Research Analyst with the Securities and Exchange Board of India ("SEBI") bearing registration Number INH000000354 as per SEBI (Research Analysts) Regulations, 2014. EGFSL hereby declares that it has not defaulted with any Stock Exchange nor its activities were suspended by any Stock Exchange with whom it is registered in last five years. However, SEBI and Stock Exchanges had conducted their routine inspection and based on their observations have issued advice letters or levied minor penalty on EGFSL for certain operational deviations in ordinary/routine course of business. EGFSL has not been debarred from doing business by any Stock Exchange / SEBI or any other authorities; nor has its certificate of registration been cancelled by SEBI at any point of time.

EGFSL offers research services to its existing clients as well as prospects. The analyst for this report certifies that all of the views expressed in this report accurately reflect his or her personal views about the subject company or companies and its or their securities, and no part of his or her compensation was, is or will be, directly or indirectly related to specific recommendations or views expressed in this report.

This report is based on information obtained from public sources and sources believed to be reliable, but no independent verification has been made nor is its accuracy or completeness guaranteed. This report and information herein is solely for informational purpose and shall not be used or considered as an offer document or solicitation of offer to buy or sell or subscribe for securities or other financial instruments. Though disseminated to all the clients simultaneously, not all clients may receive this report at the same time. The securities discussed and opinions expressed in this report may not be suitable for all investors, who must make their own investment decisions, based on their own investment objectives, financial positions and needs of specific recipient.

EGFSL and/or its affiliates may seek investment banking or other business from the company or companies that are the subject of this material. EGFSL may have issued or may issue other reports (on technical or fundamental analysis basis) of the same subject company that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Users of this report may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports of EGFSL. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of EGFSL; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest including but not limited to those stated herein. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein. All material presented in this report, unless specifically indicated otherwise, is under copyright to Emkay. None of the material, nor its content, nor any copy of it, may be altered in any way, transmitted to, copied or distributed to any other party, without the prior express written permission of EGFSL. All trademarks, service marks and logos used in this report are trademarks or registered trademarks of EGFSL or its affiliates. The information contained herein is not intended for publication or distribution or circulation in any manner whatsoever and any unauthorized reading, dissemination, distribution or copying of this communication is prohibited unless otherwise expressly authorized. Please ensure that you have read "Risk Disclosure Document for Capital Market and Derivatives Segments" as prescribed by Securities and Exchange Board of India before investing in Indian Securities Market. In so far as this report includes current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed.

This report has not been reviewed or authorized by any regulatory authority. There is no planned schedule or frequency for updating research report relating to any issuer/subject company.

Please contact the primary analyst for valuation methodologies and assumptions associated with the covered companies or price targets.

**Disclaimer for U.S. persons only:** Research report is a product of Emkay Global Financial Services Ltd., under Marco Polo Securities 15a6 chaperone service, which is the employer of the research analyst(s) who has prepared the research report. The research analyst(s) preparing the research report is/are resident outside the United States (U.S.) and are not associated persons of any U.S. regulated broker-dealer and therefore the analyst(s) is/are not subject to supervision by a U.S. broker-dealer, and is/are not required to satisfy the regulatory licensing requirements of Financial Institutions Regulatory Authority (FINRA) or required to otherwise comply with U.S. rules or regulations regarding, among other things, communications with a subject company, public appearances and trading securities held by a research analyst account.

This report is intended for distribution to "Major Institutional Investors" as defined by Rule 15a-6(b)(4) of the U.S. Securities and Exchange Act, 1934 (the Exchange Act) and interpretations thereof by U.S. Securities and Exchange Commission (SEC) in reliance on Rule 15a 6(a)(2). If the recipient of this report is not a Major Institutional Investor as specified above, then it should not act upon this report and return the same to the sender. Further, this report may not be copied, duplicated and/or transmitted onward to any U.S. person, which is not the Major Institutional Investor. In reliance on the exemption from registration provided by Rule 15a-6 of the Exchange Act and interpretations thereof by the SEC in order to conduct certain business with Major Institutional Investors. Emkay Global Financial Services Ltd. has entered into a chaperoning agreement with a U.S. registered broker-dealer, Marco Polo Securities Inc. ("Marco Polo"). Transactions in securities discussed in this research report should be effected through Marco Polo or another U.S. registered broker dealer.

This report is intended for Team White Marque Solutions ([team.emkay@whitemarquesolutions.com](mailto:team.emkay@whitemarquesolutions.com))

## RESTRICTIONS ON DISTRIBUTION

This report is not directed to, or intended for distribution to or use by, any person or entity who is a citizen or resident of or located in any locality, state, country or other jurisdiction where such distribution, publication, availability or use would be contrary to law or regulation. Except otherwise restricted by laws or regulations, this report is intended only for qualified, professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions. Specifically, this document does not constitute an offer to or solicitation to any U.S. person for the purchase or sale of any financial instrument or as an official confirmation of any transaction to any U.S. person. Unless otherwise stated, this message should not be construed as official confirmation of any transaction. No part of this document may be distributed in Canada or used by private customers in United Kingdom.

## ANALYST CERTIFICATION BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL)

The research analyst(s) primarily responsible for the content of this research report, in part or in whole, certifies that the views about the companies and their securities expressed in this report accurately reflect his/her personal views. The analyst(s) also certifies that no part of his/her compensation was, is, or will be, directly or indirectly, related to specific recommendations or views expressed in the report. The research analyst (s) primarily responsible of the content of this research report, in part or in whole, certifies that he or his associated persons<sup>1</sup> may have served as an officer, director or employee of the issuer or the new listing applicant (which includes in the case of a real estate investment trust, an officer of the management company of the real estate investment trust; and in the case of any other entity, an officer or its equivalent counterparty of the entity who is responsible for the management of the issuer or the new listing applicant). The research analyst(s) primarily responsible for the content of this research report or his associate may have Financial Interests<sup>2</sup> in relation to an issuer or a new listing applicant that the analyst reviews. EGFSL has procedures in place to eliminate, avoid and manage any potential conflicts of interests that may arise in connection with the production of research reports. The research analyst(s) responsible for this report operates as part of a separate and independent team to the investment banking function of the EGFSL and procedures are in place to ensure that confidential information held by either the research or investment banking function is handled appropriately. There is no direct link of EGFSL compensation to any specific investment banking function of the EGFSL.

<sup>1</sup> An associated person is defined as (i) who reports directly or indirectly to such a research analyst in connection with the preparation of the reports; or (ii) another person accustomed or obliged to act in accordance with the directions or instructions of the analyst.

<sup>2</sup> Financial Interest is defined as interest that are commonly known financial interest, such as investment in the securities in respect of an issuer or a new listing applicant, or financial accommodation arrangement between the issuer or the new listing applicant and the firm or analysis. This term does not include commercial lending conducted at the arm's length, or investments in any collective investment scheme other than an issuer or new listing applicant notwithstanding the fact that the scheme has investments in securities in respect of an issuer or a new listing applicant.

## COMPANY-SPECIFIC / REGULATORY DISCLOSURES BY EMKAY GLOBAL FINANCIAL SERVICES LIMITED (EGFSL):

Disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) covered in this report:-

- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her associate/relative's may have Financial Interest/proprietary positions in the securities recommended in this report as of November 14, 2025
- EGFSL, and/or Research Analyst does not market make in equity securities of the issuer(s) or company(ies) mentioned in this Report

### Disclosure of previous investment recommendation produced:

- EGFSL may have published other investment recommendations in respect of the same securities / instruments recommended in this research report during the preceding 12 months. Please contact the primary analyst listed in the first page of this report to view previous investment recommendations published by EGFSL in the preceding 12 months.
- EGFSL, its subsidiaries and/or other affiliates and Research Analyst or his/her relative's may have material conflict of interest in the securities recommended in this report as of November 14, 2025
- EGFSL, its affiliates and Research Analyst or his/her associate/relative's may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the November 14, 2025
- EGFSL or its associates may have managed or co-managed public offering of securities for the subject company in the past twelve months.
- EGFSL, its affiliates and Research Analyst or his/her associate may have received compensation in whatever form including compensation for investment banking or merchant banking or brokerage services or for products or services other than investment banking or merchant banking or brokerage services from securities recommended in this report (subject company) in the past 12 months.
- EGFSL, its affiliates and/or and Research Analyst or his/her associate may have received any compensation or other benefits from the subject company or third party in connection with this research report.

### Emkay Rating Distribution

Ratings	Expected Return within the next 12-18 months.
BUY	>15% upside
ADD	5-15% upside
REDUCE	5% upside to 15% downside
SELL	>15% downside

### Emkay Global Financial Services Ltd.

CIN - L67120MH1995PLC084899

7th Floor, The Ruby, Senapati Bapat Marg, Dadar - West, Mumbai - 400028. India

Tel: +91 22 66121212 Fax: +91 22 66121299 Web: [www.emkayglobal.com](http://www.emkayglobal.com)

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com)

**OTHER DISCLAIMERS AND DISCLOSURES:**

**Other disclosures by Emkay Global Financial Services Limited (Research Entity) and its Research Analyst under SEBI (Research Analyst) Regulations, 2014 with reference to the subject company(s) :-**

EGFSL or its associates may have financial interest in the subject company.

Research Analyst or his/her associate/relative's may have financial interest in the subject company.

EGFSL or its associates and Research Analyst or his/her associate/ relative's may have material conflict of interest in the subject company. The research Analyst or research entity (EGFSL) have not been engaged in market making activity for the subject company.

EGFSL or its associates may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst or his/her associate/relatives may have actual/beneficial ownership of 1% or more securities of the subject company at the end of the month immediately preceding the date of public appearance or publication of Research Report.

Research Analyst may have served as an officer, director or employee of the subject company.

EGFSL or its affiliates may have received any compensation including for investment banking or merchant banking or brokerage services from the subject company in the past 12 months. . Emkay may have issued or may issue other reports that are inconsistent with and reach different conclusion from the information, recommendations or information presented in this report or are contrary to those contained in this report. Emkay Investors may visit [www.emkayglobal.com](http://www.emkayglobal.com) to view all Research Reports. The views and opinions expressed in this document may or may not match or may be contrary with the views, estimates, rating, and target price of the research published by any other analyst or by associate entities of Emkay; our proprietary trading, investment businesses or other associate entities may make investment decisions that are inconsistent with the recommendations expressed herein. EGFSL or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months. EGFSL or its associates may have received any compensation or other benefits from the Subject Company or third party in connection with the research report. EGFSL or its associates may have received compensation from the subject company in the past twelve months. Subject Company may have been client of EGFSL or its affiliates during twelve months preceding the date of distribution of the research report and EGFSL or its affiliates may have co-managed public offering of securities for the subject company in the past twelve months.

This report is intended for Team White Marque Solutions (team.emkay@whitemarquesolutions.com)